BARCELONA, SPAIN -- (MARKET WIRE) -- December 13, 2006 -- ERA Biotech, a bioproductivity company improving the manufacture of recombinant proteins in cultured cells, announced today that it has concluded a EUR 1,4M financing. Invertec, Reus Capital Riesgo, Talde Capital II and Uninvest each invested 300k in convertible loans to lead the round, which also included participation by individuals and entities close to the company. "Bioproducts are at the vanguard of the health, industrial and energy sectors, and the scale and efficiency of manufacturing still lag demand," explained François Arcand, ERA's CEO. "Our investors recognized that ERA Biotech is creating innovative solutions that directly improve the bottom lines of billion-dollar businesses."
